Head-to-head evidence
Burixafor (TG-0054) vs Motixafortide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
Burixafor (TG-0054)
Developed by GPCR Therapeutics, Inc.
NCT01018979 · Phase 2 · completed
Although this study assigned patients to two dose levels, it had no placebo or active-comparator arm and was fully open-label (no masking), so there was no control against which to judge the drug's effect. Only 19 patients were treated, and most (13 of 19) dropped out before completing collection because their stem cell counts never rose high enough, leaving just 4 and 3 patients per dose group who even underwent apheresis for the primary mobilization-success endpoint. With no control arm and such a small, high-dropout sample, this is uncontrolled, exploratory evidence rather than a definitive efficacy trial.
Motixafortide
Marketed by Ayrmid Ltd. and partners
NCT02639559 · Phase 2 · completed
The study was non-randomized, open-label, and had no comparator arm, with 50 participants overall and 24 evaluable donors for the primary endpoint. Although 22 of 24 donors met the mobilization target, this uncontrolled design cannot establish how motixafortide compares with another mobilization strategy; the primary endpoint was a CD34+ cell mobilization measure rather than a direct clinical outcome.
Next expected readout: December 2026 · NCT07101445 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Burixafor (TG-0054)'s landscape · Motixafortide's landscape